[HTML] frontiersin.org

[HTML][HTML] Prognostic factors for checkpoint inhibitor based immunotherapy: an update with new evidences

X Yan, S Zhang, Y Deng, P Wang, Q Hou… - Frontiers in …, 2018 - frontiersin.org
Checkpoint inhibitor (CPI) based immunotherapy (ie, anit-CTLA-4/PD-1/PD-L1 antibodies)
can effectively prolong overall survival of patients across several cancer types at the …
被引用次数：66 相关文章

[引用][C] Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences

X Yan, S Zhang, Y Deng, P Wang, Q Hou… - Frontiers in …, 2018 - cir.nii.ac.jp
Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New
Evidences | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
[HTML] nih.gov

[HTML][HTML] Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences

X Yan, S Zhang, Y Deng, P Wang, Q Hou… - Frontiers in …, 2018 - ncbi.nlm.nih.gov
Checkpoint inhibitor (CPI) based immunotherapy (ie, anit-CTLA-4/PD-1/PD-L1 antibodies)
can effectively prolong overall survival of patients across several cancer types at the …

Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences

X Yan, S Zhang, Y Deng, P Wang… - … the PD-1/PD-L1 Cancer …, 2020 - books.google.com
Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New
Evidences Page 38 REVIEW published: 20 September 2018 doi: 10.3389/fphar. 2018.01050 …

Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences.

X Yan, S Zhang, Y Deng, P Wang, Q Hou… - Frontiers in …, 2018 - europepmc.org
Checkpoint inhibitor (CPI) based immunotherapy (ie, anit-CTLA-4/PD-1/PD-L1 antibodies)
can effectively prolong overall survival of patients across several cancer types at the …
[PDF] researchgate.net

[PDF][PDF] Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences

X Yan, S Zhang, Y Deng, P Wang, Q Hou… - Targeting the PD …, 2020 - researchgate.net
Checkpoint inhibitor (CPI) based immunotherapy (ie, anit-CTLA-4/PD-1/PD-L1 antibodies)
can effectively prolong overall survival of patients across several cancer types at the …

Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences

X Yan, S Zhang, Y Deng, P Wang… - Frontiers in …, 2018 - pubmed.ncbi.nlm.nih.gov
Checkpoint inhibitor (CPI) based immunotherapy (ie, anit-CTLA-4/PD-1/PD-L1 antibodies)
can effectively prolong overall survival of patients across several cancer types at the …